FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Zalevsky Jonathan						2. Issuer Name and Ticker or Trading Symbol NEKTAR THERAPEUTICS [ NKTR ]								5. Relationship of Reporting Person(s) to Is (Check all applicable)  Director 10% O  X Officer (give title Other)					ner	
(Last) (First) (Middle) C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH					3. Date of Earliest Transaction (Month/Day/Year) 10/12/2021									below)			below)			
(Street) SAN FRANCI			94158 (Zip)		4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)								. Indivine)	′					
		Tab	le I - Nor	n-Deriv	/ativ	e Se	curities	s Acq	juired, D	ispos	ed o	f, or Be	neficia	ally	Owned					
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					Execution Dat		Date,	Code (Instr.					4 and Securitie Benefici Owned F		es Fo ally (D) Following (I)		rm: Direct	7. Nature of Indirect Beneficial Ownership		
									Code V	An	nount	(A) or (D)		е	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date, 7	Code (Inst				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		D	. Price of erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
Code V (A) (D)							Date Exercisable	Expira Date	ation	Title	Amour or Number of Shares	er								
Stock Option <sup>(1)</sup>	\$21.79	10/12/2021 <sup>(2)</sup>			A		71,550		(3)	12/11	/2027	Common Stock	71,55	0	\$0.00	71,550	)	D		

- 1. These stock options were granted on December 12, 2019 under the Company's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements.
- 2. The Organization and Compensation Committee of the Board of Directors of the Company determined that the performance-based vesting requirement for these stock options was satisfied on September 15, 2021. Pursuant to the terms of the 2017 Plan, these stock options vested on the next monthly vesting date (October 12, 2021) following the date that the performance-based vesting requirement was satisfied.
- 3. These stock options vest on a monthly pro-rata basis over a period of four years from the grant date (December 12, 2019).

## Remarks:

Mark A. Wilson, Attorney-in-

**Fact** 

10/14/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.